Upload
others
View
1
Download
0
Embed Size (px)
Citation preview
5/3/2019
1
WHAT I WANT FROM MY ENDOCRINE SURGEON?
DR. VANITHA SINGARAM, MD, FACEENDOCRINOLOGIST
IOWA DIABETES AND ENDOCRINOLOGY CENTER
PRE-LECTURE SURVEY
• 52 YEAR OLD MAN WITH A 5 CM RIGHT THYROID NODULE, FNA REVEALS PAPILLARY THYROID CARCINOMA. NEXT STEP?
A. TOTAL THYROIDECTOMY
B. TOTAL THYROIDECTOMY WITH CENTRAL COMPARTMENTDISSECTION
C. US OR CT NECK
D. PET
5/3/2019
2
PRE-LECTURE SURVEY
35 YR. OLD FEMALE WITH HYPERCALCEMIA, PARATHYROID LABS HIGHNORMAL, RECURRENT RENAL CALCULI ( CALCIUM STONES ), 24. HR. URINE CALCIUM 250 MG, SESTAMIBI SCAN DID NOT LOCALIZE ANADENOMA ? NEXT STEP ?
a. MEDICAL SURVEILLANCE
b. REPEAT SCAN
c. SURGERY PARATHYROID EXPLORATION
d. REPEAT 24 HR. URINE CALCIUM TO EVALUATE FOR FAMILIALHYPOCALCIURIC HYPERCALCEMIA
PRE-LECTURE SURVEY
• 48 YEAR OLD WOMAN WITH 6.3 CM ENHANCINGHETEROGENOUS RIGHT ADRENAL MASS. SHE ISOTHERWISE HEALTHY WITH NO HISTORY OFHYPERTENSION OR SYSTEMIC ILLNESS. NEXT STEP?A. CT-GUIDED BIOPSY OF MASS
B. RIGHT ADRENALECTOMY
C. CHECK SERUM METANEPHRINES
D. URINARY VMAE. NO FURTHER INTERVENTION
5/3/2019
3
DISCLAIMERS AND DISCLOSURES
• NO FINANCIAL CONFLICTS OF INTEREST
• NO OFF-LABEL DISCUSSION
OBJECTIVES AND SCOPE
• PROVIDE AN APPROACH TO WORKING UPINCIDENTALLY DISCOVERED ENDOCRINE NODULES
• BRIDGE THE SURGICAL AND THE CLINICAL WORLDS
• THYROID NODULES AND DIFFERENTIATED THYROIDCANCER
• PRIMARY HYPERPARATHYROIDISM
• ADRENAL INCIDENTALOMAS INCLUDING PRIMARYHYPERALDOSTERONISM ANDPHEOCHROMOCYTOMA
5/3/2019
4
THYROID INCIDENTALOMAS• COMMON:
• PREVALENCE ( PALPATION ) : 5 % IN WOMEN, 1 % IN MEN
• SONOGRAPHIC PREVALENCE UP TO 68 %
• INCREASES WITH AGE
• 27% IN < 50 YEAR OLDS
• ~50% OF 50 YEAR OLDS
• MORE COMMON IN WOMEN
• KEY QUESTIONS :
• ARE THEY AFFECTING THYROID FUNCTION? SERUM TSH
• ARE THEY MALIGNANT? NO ROLE FOR SERUM THYROGLOBULIN
Ezzat S. Arch Int Med 1994 Brander A. Radiology 1991
EVALUATION:
• LABS: TSH TO ASSESS FOR HYPERTHYROIDISM
• IF HYPERTHYROID- POSSIBILITY OF A HOT NODULE
• NEXT STEP : I-123 UPTAKE & SCAN +/- REFERRAL TOENDOCRINOLOGIST TO EVALUATE NEED FOR TREATMENT ANDDISCUSS TREATMENT OPTIONS.
• IMAGING: HIGH-SENSITIVITY ULTRASONOGRAPHY
• SONOGRAPHIC RISK FACTORS
• HYPOECHOIC NODULES
• IRREGULAR MARGINS
• INCREASED VASCULARITY
• MICROCALCIFICATIONS
Gharib H. Endocrinol Metab Clin N Am 2007
5/3/2019
5
OTHER MODALITIES :
• FDG-PET – FOCAL UPTAKE WITH US CONFIRMED NODULES > 1 CMWARRANT FNA
• FDG-PET – DIFFUSE UPTAKE WITH US AND BIOCHEMICAL EVIDENCEOF CHRONIC LYMPHOCYTIC THYROIDITIS DOES NOT WARRANT FNA
• CT/MRI:• ONLY IF SUBSTERNAL, NODE MAPPING
• RADIONUCLIDE UPTAKE & SCAN
• ONLY IF HYPERTHYROID- TO CONFIRM HOT NODULE
• COLD NODULE = MALIGNANCY?• BUT MOST COLD NODULES ARE BENIGN
• AND MANY CANCERS DON’T APPEAR COLD ON IMAGING
5/3/2019
6
ULTRASOUND-GUIDED THYROID BIOPSY
• US-GUIDED FNA• GOLD STANDARD
• OFFICE BASED
• MULTIPLE NODULES: • SONOGRAPHIC SUSPICION
Khoo TK. Endocr Prac 2008 AACE/AME Task Force on Thyroid nodules. Endocr Prac 2006
5/3/2019
7
RESULTS AND IMPLICATIONS
• DIAGNOSTIC
• BENIGN
• ATYPIA OR FOLLICULAR LESION OF UNDETERMINED SIGNIFICANCE
• SUSPICIOUS FOR FOLLICULAR NEOPLASM OR MALIGNANCY
• MALIGNANT
• NONDIAGNOSTIC
Cibas ES. Am J Clin Pathol 2009
ROLE OF MOLECULAR MARKERS
1. AFFIRMA GENE EXPRESSION CLASSIFIER :- MRNA EXPRESSION OF 167 GENES
- NPV 95 % IN ATYPIA OF UNKNOWN SIGNIFICANCE/FOLLICULAR LESION OF
UNKNOW SIGNIFICANCE, FOLLICULAR NEOPLASM ( BETHESDA III&IV)- PPV 37 %- GOOD ‘RULE OUT’ TEST IN INDETERMINATE NODULES.
2. THYGENX AND THYRAMIR :- GENE MUTATION : BRAF, RAS, RET/PET, PAX8/PPARΓ- NPV 94 %, PPV 74 %
3. THYROSEQ : - GENE MUTATION & FUSION PANEL
- NPV 96 %, PPV 88 %, ‘RULE IN’ TEST
LONG-TERM OUTCOME DATA INSUFFICIENT AT THIS POINT
5/3/2019
8
THYROID MALIGNANCY
• ONLY 1 IN 20 NODULES IS MALIGNANT
• 1% OF ALL CANCERS
• 1975-2009 : INCIDENCE : 4.9 TO 14.3 /100,000
MORTALITY : STABLE 0.5 /100,000
Davies L. JAMA Otolaryngol Head & Neck Surgery 2014
Davies L. JAMA 2006
5/3/2019
9
SUBTYPES
• FOLLICULAR-DERIVED
• DIFFERENTIATED
• 80 % PAPILLARY THYROID CARCINOMA (VARIANTS- TALL CELL, FOLLICULAR, CLEAR CELL)
• 10 %FOLLICULAR THYROID CARCINOMA (HURTHLE CELL)
• 1-2 % UNDIFFERENTIATED/ANAPLASTIC
• 5 -10 % MEDULLARY
• RARE – PRIMARY LYMPHOMAS & SARCOMA
PAPILLARY THYROID CARCINOMA
• INCIDENCE 8:100,000• MICROPTC IN UP TO 30% OF AUTOPSIES
• ~80% OF THYROID CANCERS
• 50% ARE ≤ 1 CM
• FEMALES > MALES
• RISK FACTORS
• RADIATION EXPOSURE
• FAMILY HISTORY
Davies L. JAMA 2006 Schlumberger MJ. N Engl J Med 1998
5/3/2019
10
PAPILLARY THYROID CARCINOMA
• COMMONLY MULTICENTRIC- 20-80% OF CASES
• LYMPH NODE METASTASIS
• METS TO REGIONAL NODES UP TO 80%, EVEN IF SMALL, INTRATHYROIDAL
• PRE-OPERATIVE NODAL EVALUATION SHOULD BE UNDERTAKEN!
• U/S TO ASSESS LATERAL COMPARTMENTS
• CT IF LIMITED EXPERIENCE IN U/S
Schlumberger MJ. N Engl J Med 1998 Mazzaferri EL. Am J Med 1994 ATA Guidelines 2006
FOLLICULAR THYROID CARCINOMA
• DISTINGUISHED FROM FOLLICULAR ADENOMAS FROM INVASION OFCAPSULE AND VESSELS
• 10% OF THYROID CANCERS
• LESS FREQUENTLY MULTICENTRIC, NODAL METS
• HEMATOLOGIC METASTASES TO LUNGS, BONES
• SLIGHTLY POORER PROGNOSIS
Schlumberger MJ. N Engl J Med 1998
5/3/2019
11
TREATMENT: 3 STEP PROCESS
• THYROIDECTOMY
• PTC- ROUTINE CENTRAL COMPARTMENT DISSECTION?
• 50% INVOLVEMENT
• THYROID SUPPRESSION THERAPY – LEVOTHYROXINE 1.6MCG/KG & REFER BACKTO ENDOCRINOLOGIST TO ASSESS NEED FOR RAI AND PLAN SURVEILLANCE
• RADIOIODINE REMNANT ABLATION
• LOW RISK : NO RAI, FOLLOW WITH ULTRASOUND AND THYROGLOBULINLEVELS.
• HIGH RISK : RECOMBINANT TSH STIMULATED REMANANT ABLATION
• NOT BE USED TO ‘CLEAN UP’ INADEQUATE SURGERY
ATA Guidelines. Thyroid 2006 Hay I. Endocr Prac 2007 Mazzaferri EJ. Endocr Prac 2007
SUMMARY
• THYROID NODULES ARE COMMON:- BIOCHEMICAL TESTING : TSH- BASED ON SIZE & CHARACTERISTICS : FNA• FOR PTC, STRONGLY CONSIDER PRE-OP NODAL IMAGING
• CONSIDER CENTRAL COMPARTMENT DISSECTION FOR SELECTCASES
• THYROID HORMONE REPLACEMENT : 1.6 MCG/KG/BODYWEIGHT
• COMMUNICATE/REFER BACK TO ASSESS NEED FOR RAI
5/3/2019
12
PRIMARY HYPERPARATHYROIDISM
• 1% OF ADULT POPULATION
• 2% OR MORE > AGE 55
• 80-85% PARATHYROID ADENOMA
• 10 % MULTI GLAND HYPERPLASIA
• 4 % DOUBLE GLAND ADENOMA
• 1% CARCINOMA
• OVEREXPRESSION OF CYCLIN D1 & DEFICIENCY OF MEN-1
• PARATHYROIDECTOMY IS THE ONLY CURATIVE TREATMENT
DIAGNOSIS
• PERSISTENT HYPERCALCEMIA OR HIGH NORMAL CALCIUM LEVEL
• INAPPROPRIATELY NORMAL OR ELEVATED PARATHYROID LEVELS
• 24 HR. URINE CALCIUM AND CREATININE
• CA/CR < 0.01 SUGGESTS FHH
• PARATHYROID IMAGING DOES NOT AID DIAGNOSIS
5/3/2019
13
IMAGING MODALITIES
• 99MTC- SESTAMIBI SCAN – SENSITIVITY : 88 % ADENOMA, 44 % HYPERPLASIA, 29 % WITH DOUBLE ADENOMA, 33 % CARCINOMA
• HIGH RESOLUTION ULTRASOUND
• SINGLE PHOTON EMISSION CT
• NO SUBSTITUTE TO AN EXPERIENCE SURGEON !!!
• MINIMALLY INVASIVE PARATHYROIDECTOMY
• 4 GLAND EXPLORATION IN 20-40 % - NEGATIVE OR EQUIVOCALSCAN
• INTRA-OPERATIVE PTH LEVELS – GREATER CERTAINTY OF CURE
INDICATIONS FOR SURGERY
• NIH +NIDDK PANEL 2002
1. AGE < 50
2. CANNOT PARTICIPATE IN MEDICAL FOLLOW-UP
3. SERUM CALCIUM > 1MG/DL ABOVE UPPER LIMIT OF NORMAL
4. URINARY CALCIUM >400 MG/24
5. + 30 % DECLINE IN RENAL FUNCTION
6. NEPHROCALCINOSIS, OSTEOPOROSIS, PSYCHONEUROLOGICDISORDER
5/3/2019
14
ADRENAL INCIDENTALOMAS
• NOT UNCOMMON EITHER!• 4-10% OF ABDOMINAL SCANNING
• AGE-DEPENDENT
• QUESTIONS
• IS THIS WORRISOME?• IS THIS AFFECTING THE FUNCTION?
Bovio S. J Endocrinol Invest 2006 Terzolo M. Eur J Endocrinol 2011
“IS THIS WORRISOME?”
• NEED A GOOD RADIOLOGIST!• IMAGING OF CHOICE- TRIPHASIC CT (MRI FOR PHEO)• BENIGN PHENOTYPE:
• SIZE <4CM, MARGINS
• DENSITY
• HOUNSFIELD UNITS <10, >50% WASHOUT
• WORRISOME PHENOTYPE
• MICROCALCIFICATIONS
• ADRENOCORTICAL CARCINOMA
• HETEROGENOUS OR CYSTIC CHANGES
• NO ROLE FOR CT-GUIDED BIOPSY!
Szolar DH. Radiology 2005
5/3/2019
15
“IS THIS HYPERFUNCTIONING?”
Bovio S. J Endocrinol Invest 2006 Terzolo M. Eur J Endocrinol 2011
Aldosterone
Cortisol
Androgens
Catecholamines
PRIMARY HYPERALDOSTERONISM
• ALDOSTERONE PRIMARILY CONTROLLED BY RENIN-ANGIOTENSINSYSTEM, NOT ACTH
• OVERPRODUCTION LEADS TO SALT RETENTION AND CLINICALHYPERTENSION
• MAY SEE HYPOKALEMIA (9-37%)
• NOT HYPERNATREMIA
Mulatero P. J Clin Endocrinol Metab 2004
5/3/2019
16
INVESTIGATIONS
• SCREEN: 8 AM ALDOSTERONE:RENIN
• >30:1 & HIGH ABSOLUTE ALDOSTERONE >15
• CONFIRMATION
• ORAL SALT LOADING: URINE NA >200 MG AND URINEALDOSTERONE >12 IN 24 HOURS
• SALINE INFUSION: 2 LITERS OVER 4 HOURS, SERUM ALDOSTERONE<10
Endocrine Society Clinical Practice Guideline 2008 Giacchetti G. J Hypertens 2006
TREATMENT
• MEDICAL THERAPY
• SPIRONOLACTONE OR EPLERENONE
• HIGHLY EFFECTIVE
• UNILATERAL ADRENALECTOMY
• MUST BE PRECEDED BY ADRENAL VEIN SAMPLING TO CONFIRMUNILATERAL, IPSILATERAL DISEASE
• ALDOSTERONE, CORTISOL SAMPLES TAKEN AND COMPARED
Young WF. Surgery 2004
5/3/2019
17
PHEOCHROMOCYTOMA
• TUMORS OF NEUROENDOCRINE CELLS
• CATECHOLAMINE-PRODUCING
• EPINEPHRINE, NOREPINEPHRINE
• ANNUAL INCIDENCE >0.8 PER 100,000
CLINICAL FEATURES
• CLASSICAL: HEADACHES, DIAPHORESIS, PALPITATIONS
• OTHERS: PAROXYSMAL HYPERTENSION, PALLOR, TREMORS, ANXIETY ATTACKS, ETC
Stein PP. Medicine 1991
5/3/2019
18
HOWEVER:
• 10-49% PRESENT AS INCIDENTAL FINDING
• UP TO 57.6% WERE ASYMPTOMATIC
• THE MOST COMMON SIGN WAS HYPERTENSION
• OFTEN SUSTAINED (NOT PAROXYSMAL)
• OFTEN WELL-CONTROLLED WITH MEDICATIONS
• SO, THE CLASSIC TRIAD, IS RARE
• CANNOT RULE OUT PHEO ON BASIS OF HISTORY
Kudva YC. The Endocrinologist 1999 Baguet JP. Eur J Endocrinol 2004 Motta-Ramirez GA. Am K Roentgenol 2005
INVESTIGATIONS: BIOCHEMISTRY
• FRACTIONATED PLASMA METANEPHRINES OR
• 24-HOUR URINE CATECHOLAMINES AND METANEPHRINES
• BEWARE OF INTERFERING MEDICATIONS AND FALSE POSITIVES
• PHEOS >2X ABOVE UPPER LIMIT
• (VMA HAS POOR SENSITIVITY AND SPECIFICITY)
Sawka AM. J Clin Endocrinol Metab 2003 Lenders JW. JAMA 2002
5/3/2019
19
INVESTIGATIONS: IMAGING
• CT
• CYSTIC/HEMORRHAGIC CHANGES
• HYPERINTENSE WITH >20 HU, VASCULAR
• MRI MIGHT BE SUPERIOR TO CT
• HYPERINTENSE ON T2 IMAGES
• MIBG OR PET IF NOT LOCALIZABLE
Baid SK. Ann Intern Med 2009
TREATMENT
• SURGERY, BUT REQUIRES MEDICAL PREPARATIONFIRST
• ALPHA BLOCKADE- PHENOXYBENZAMINE 10 MGBID, INCREASING TO GOAL
• PRAZOSIN, DOXAZOSIN FOR LONGTERM
• OTHERS: LABETOLOL, NICARDIPINE, • REPEAT BIOCHEMISTRY POST-OP AND ANNUALLY
Amar L. J Clin Endocrinol Metab 2005
5/3/2019
20
OTHER TESTS
• CORTISOL: 1 MG OVERNIGHT DEXAMETHASONESUPPRESSION TEST
• ANDROGEN: DHEA
IF NONFUNCTIONING:
• IF NO WORRISOME PHENOTYPE, REPEAT IMAGING IN 6 AND 12 MONTHS.
• REPEAT BIOCHEMISTRY FOR ALDOSTERONE AND CATECHOLAMINEANNUALLY?
Terzolo M. Eur J Endocrinol 2011
5/3/2019
21
SUMMARY• BIOCHEMICAL TESTING IS MANDATORY FOR ALL ADRENAL
INCIDENTALOMAS
• LACK OF SYMPTOMS DOES NOT NEGATE TESTING
• HYPERALDOSTERONISM IS NOT ALWAYS SURGICAL
• MEDICAL PREPARATION IS CRITICAL FOR PHEOCHROMOCYTOMA
POST-LECTURE SURVEY
• 52 YEAR OLD MAN WITH A 5 CM THYROID NODULE, FNA REVEALSPAPILLARY THYROID CARCINOMA. NEXT STEP?
A. THYROIDECTOMY
B. THYROIDECTOMY WITH CENTRAL COMPARTMENT DISSECTION
C. US OR CT NECK
D. PET
5/3/2019
22
POST-LECTURE SURVEY
35 YR. OLD FEMALE WITH HYPERCALCEMIA, PARATHYROID LABS HIGH NORMAL, RECURRENT RENAL CALCULI ( CALCIUM STONES ), 24. HR. URINE CALCIUM 250 MG, SESTAMIBI SCAN DID NOT LOCALIZE AN ADENOMA ? NEXT STEP ?
a. MEDICAL SURVEILLANCE
b. REPEAT SCAN
c. SURGERY PARATHYROID EXPLORATION
d. REPEAT 24 HR. URINE CALCIUM TO EVALUATE FOR FAMILIAL HYPOCALCIURICHYPERCALCEMIA
POST-LECTURE SURVEY
• 48 YEAR OLD WOMAN WITH 6.3 CM ENHANCINGHETEROGENOUS RIGHT ADRENAL MASS. SHE ISOTHERWISE HEALTHY WITH NO HISTORY OFHYPERTENSION OR SYSTEMIC ILLNESS. NEXT STEP?A. CT-GUIDED BIOPSY OF MASS
B. RIGHT ADRENALECTOMY
C. CHECK SERUM METANEPHRINES
D. URINARY VMAE. NO FURTHER INTERVENTION
5/3/2019
23
QUESTIONS/DISCUSSION